- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: SCH 530348 | SCH-530348 | SCH530348 | Zontivity®
vorapaxar is an approved drug (FDA (2014))
Compound class: Synthetic organic
Comment: Vorapaxar is an orally active thrombin receptor (PAR1) antagonist based on the natural product himbacine , that is used as an anti-thrombosis drug.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: vorapaxar
1. Chackalamannil S, Wang Y, Greenlee WJ, Hu Z, Xia Y, Ahn HS, Boykow G, Hsieh Y, Palamanda J, Agans-Fantuzzi J et al.. (2008)
Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity.
J Med Chem, 51 (11): 3061-4. [PMID:18447380]
2. Sriram K, Insel PA. (2020)
Proteinase-activated receptor 1: A target for repurposing in the treatment of COVID-19?.
Br J Pharmacol, 177 (21): 4971-4974. [PMID:32639031]
3. Ueno M, Ferreiro JL, Angiolillo DJ. (2010)
Mechanism of action and clinical development of platelet thrombin receptor antagonists.
Expert Rev Cardiovasc Ther, 8 (8): 1191-200. [PMID:20670195]